Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Severe Chronic Neutropenia International Registry
Benign Hematologic
Benign Hematologic
Benign Hematologic
N/A
McDaniel, Heather
VICCNCPED10104
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Hematologic
Hematologic
The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries. Objectives: To learn more about what makes stem cell transplants and cellular therapies work well such as: - Determine how well recipients recover from their transplants or cellular therapy; - Determine how recovery after a transplant or cellular therapy can be improved; - Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy; - Determine how access to transplant or cellular therapy for different groups of patients can be improved; - Determine how well donors recover from the collection procedures.
Hematologic
N/A
Byrne, Michael
NCT01166009
VICCBMT1110
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hematologic
Hematologic
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Hematologic
N/A
Kassim, Adetola
NCT01351545
VICCBMT1158
Mutations in DICER1 and Related MicroRNA Processing Genes in Dysplasias, Dysontogenic Diseases, Tumors and Other Conditions
Pediatric Solid Tumors
Pediatric Solid Tumors
Pediatric Solid Tumors
N/A
Esbenshade, Adam
VICCPED1258
A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies
Sickle Cell
Sickle Cell
Sickle Cell
N/A
Kassim, Adetola
NCT01850108
VICCNCBMT12108
Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)
Leukemia
Leukemia
Leukemia
N/A
Ferrell, Paul
VICCHEM1305
Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)
Bladder
Bladder
Bladder
N/A
Arnold, Shanna
VICCURO1322
Neratinib HER Mutation Basket Study (SUMMIT)
Multiple Cancer Types
This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.
Bladder,
Colon,
Esophageal,
Gastric/Gastroesophageal,
Neuro-Oncology,
Ovarian,
Urologic,
Uterine
II
Mayer, Ingrid
NCT01953926
VICCMD1403
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and / or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma. Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing / Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents.
Not Available
II
Keedy, Vicki
NCT02048371
VICCSAR1483
